Issue link: https://viewer.e-digitaledition.com/i/978233
Cancer Drugs: Cost vs. Affordability R E D U C E D P R I C E S F O R cancer drugs in middle-income countries do not ensure the drugs are as affordable to patients in those nations as they are to patients in high-income nations, according to a study published in Oncotarget. Researchers assessed affordability in high-income countries including the United States, Australia, Israel and the United Kingdom, upper-middle-income countries including China and South Africa, and one lower-middle-income country, India. Despite often signifi cantly lower prices for the drugs in middle-income nations, disparities in wealth rendered patients in those nations less able to afford the drugs. This held true whether average salary or gross domestic product was the benchmark for determining a nation's wealth. Researchers suggested that differential pricing worldwide for hepatitis C drugs — accomplished with government and industry partnerships that discouraged development of a black market — could be a model for making cancer drugs more affordable. ■ — Steve Barrett Lung Cancer Treatment Varies by Insurance Type PAT I E N T S W I T H N O N M E TA S TAT I C small-cell lung cancer are less likely to receive both chemotherapy and thoracic radiation — the standard of care for initial management of the disease — if they rely on federal programs such as Medicare or Medicaid than if they have private insurance, according to researchers at The University of Texas MD Anderson Cancer Center. There was no difference in rates at which patients on government programs versus private insurance received chemotherapy, the study found. However, those on Medicare or Medicaid were less likely to receive both chemotherapy and radiation, noted Senior Author Stephen G. Chun, MD, Assistant Professor of Radiation Oncology at MD Anderson. Patients with no form of insurance were less likely to receive either. Median survival was 18.2 months for patients who underwent chemotherapy and radiation. For those undergoing chemotherapy or radiation alone, median survival was 10.5 and 8.3 months, respectively. Those receiving neither had median survival of 3.7 months. The fi ndings appear in JAMA Oncology. ■ — Steve Barrett The EHR Blues O P H T H A L M O L O G I S T S A R E M A K I N G a lot more use of EHR systems these days but fi nding them less valuable, according to a survey whose results were published in JAMA Ophthalmology. Usage among this group of specialists more than doubled from 2006 to 2016. However, that corresponded with a marked drop in satisfaction with the systems. In a 2006 survey, approximately 15 percent of respondents said adopting EHR harmed productivity. That rose to more than half by 2016. Also in 2006, only 13 percent believed EHR had increased their costs, whereas 75 percent held that view in the most recent survey. "Our fi ndings highlight the fact that companies that design EHR systems should further address the effi ciency and usability of those systems," lead author Michele C. Lim, Vice Chair and Medical Director of the University of California, Davis Eye Center, said in a news release. ■ — Steve Barrett B U S I N E S S O F M E D I C I N E ❰❰❰❰❰ 1 1 M D N E W S . C O M /// M D N E W S L O W E R H U D S O N / B R O N X ■ 2 018 1 1

